IRIS
LAURIA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.570
EU - Europa 4.029
AS - Asia 834
SA - Sud America 17
AF - Africa 8
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.465
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.557
GB - Regno Unito 1.031
IE - Irlanda 820
CN - Cina 634
UA - Ucraina 550
SE - Svezia 389
RU - Federazione Russa 338
FR - Francia 287
DE - Germania 224
IT - Italia 183
FI - Finlandia 134
SG - Singapore 132
BE - Belgio 17
CZ - Repubblica Ceca 15
VN - Vietnam 15
TR - Turchia 12
CA - Canada 11
NL - Olanda 9
BR - Brasile 7
CI - Costa d'Avorio 6
ES - Italia 6
JP - Giappone 6
CL - Cile 5
HR - Croazia 5
EE - Estonia 4
HK - Hong Kong 4
IN - India 4
LT - Lituania 4
AR - Argentina 3
AU - Australia 3
IR - Iran 3
KG - Kirghizistan 3
MY - Malesia 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
EU - Europa 2
GR - Grecia 2
ID - Indonesia 2
IL - Israele 2
MX - Messico 2
NZ - Nuova Zelanda 2
PL - Polonia 2
SK - Slovacchia (Repubblica Slovacca) 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AT - Austria 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
DK - Danimarca 1
EG - Egitto 1
GE - Georgia 1
JO - Giordania 1
KR - Corea 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
Totale 11.465
Salva come PNG Salva come JPEG
Città #
Fairfield 1.195
Southend 946
Dublin 818
Ashburn 568
Woodbridge 564
Seattle 468
Jacksonville 454
Wilmington 425
Houston 424
Chandler 397
Santa Clara 395
Cambridge 394
Ann Arbor 208
Princeton 174
Nanjing 164
Beijing 138
Singapore 94
Siena 91
Nanchang 57
Boardman 52
San Diego 50
Helsinki 43
San Mateo 39
Moscow 38
Shenyang 33
Tianjin 30
Hebei 28
Shanghai 27
Kunming 22
London 22
Norwalk 20
Falls Church 19
Jiaxing 18
Brussels 17
Changsha 17
Dearborn 16
San Francisco 16
Dong Ket 14
Düsseldorf 14
Hangzhou 14
Zhengzhou 14
Brno 13
Menlo Park 13
Ningbo 12
New York 11
Izmir 9
Munich 9
Toronto 9
Lancaster 8
Lanzhou 8
Los Angeles 8
Washington 8
São Paulo 7
Abidjan 6
Jinan 6
Málaga 6
Taizhou 6
Changchun 5
Frankfurt am Main 5
Tokyo 5
Zagreb 5
Chicago 4
Dallas 4
Edinburgh 4
Fremont 4
Guangzhou 4
Indiana 4
Rome 4
Tallinn 4
Amsterdam 3
Annecy 3
Bishkek 3
Chiswick 3
Colle Di Val D'elsa 3
Detroit 3
Paris 3
Philadelphia 3
Piacenza 3
Venezia 3
Auburn Hills 2
Bangkok 2
Berlin 2
Birmingham 2
Bratislava 2
Canberra 2
Central 2
Cherbourg-Octeville 2
Córdoba 2
Dubai 2
Fuzhou 2
Groningen 2
Haikou 2
Hounslow 2
Kilburn 2
Lappeenranta 2
Mestre 2
Milan 2
New Bedfont 2
Newcastle upon Tyne 2
Paliano 2
Totale 8.800
Salva come PNG Salva come JPEG
Nome #
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 216
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 177
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 176
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 175
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 172
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 171
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 170
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 170
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 169
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 162
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 161
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 161
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 160
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 157
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 156
Emerging drugs in chronic myelogenous leukaemia 153
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 153
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 152
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 150
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 150
Towards the pharmacotherapy of hairy cell leukaemia 149
Predicting the clinical course of Hodgkin lymphoma 149
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 148
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 148
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 148
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 146
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 144
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 143
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 141
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 139
Typical genomic imbalances in primary MALT lymphoma of the orbit 139
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 137
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 134
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 134
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 132
Alternative methods of cladribine administration 131
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 131
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 130
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 130
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 129
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 126
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 125
The effects of zoledronic acid on serum lipids in multiple myeloma patients 122
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 120
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 117
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 117
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 117
Reply to “Rituximab activity in CD20-positive multiple myeloma” 116
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 116
Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey 116
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 111
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance 111
Combination therapies to improve the long-term outcome in hairy cell leukemia 110
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 110
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch 109
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 109
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 107
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 106
Comparison of low-dose versus standard-dose alpha-interferon regimen in the hairy cell leukemia treatment 105
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 105
Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia 102
Vaccinoterapia antitumorale: il modello della leucemia mieloide cronica. 101
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 100
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib 100
Hairy cell leukemias (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes 99
CD30 positive (non-anaplastic) peripheral T cell lymphoma of the thyroid gland 99
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients 97
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency 96
Bcr-abl peptides for chronic myeloid leukemia. 94
Favorable impact of low dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non Hodgkin’s lymphomas 93
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma 93
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate 93
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 92
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas 91
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 90
Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years 88
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 88
Evaluation of Ph+/CD34+ residual cells in chronic myeloid leukemia patients after long lasting treatment with imatinib mesylate 87
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia : a new treatment schedule effective and safer in preventing infective complications 86
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 84
EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES (MABTHERA) IN PATIENTS WITH PROGRESSED HAIRY CELL LEUKEMIA. 82
Case-control study of multidrug resistance phenotype and response to induction treatment includine or not fludarabine in newly diagnosed acute myeloid leukemia patients 82
Hyperlipidemic myeloma 81
CMLVAX100 Peptide Vaccinations induce Peptide Specific "cytotoxic" CD4+ T Cells (CD4+CTLs) in Chronic Myeloid Leukemia Patients: New Insights about Peptide Vaccine-Mediated Antitumor Response 81
Deletion 9q in a patient with concomitant myelodisplasia and non-Hodgkin lymphoma 80
CD4+/CD45RA+ “naive” T cells and immunological response to influenza virus vaccine in B-cell chromnic lymphocitic leukemia patients 78
Imatinib plus CMLVAX100 (P210-derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukemia (CML) showing persistent residual disease during treatment with imatinib mesylate 77
Imatinib mesylate in the treatment of c-kit positive acute myeloid leukemia: is the real target? 76
Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia 73
Low-dose fludarabine and cyclophosohamide in elderly patients with B-cell chronic lymphocytic leukemia refractory in conventional theraphy 73
Promyelocytic blast crisis of chronic myelogenous leukaemia during imatinib treatment. 71
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 68
Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia 65
Long-lasting complete remission in patients with hairy cell leukemia trated with 2-CdA: a 5-year survey 64
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC) 63
Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Entercoccus faecium 52
null 34
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study 34
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines 30
297. Gozzetti A.,Tozzuoli D., Crupi R., Gentili S., Raspadori D., Fabbri A., Lauria F. A t(20;21) (q2;q22.3) in a patient with chronic myelocytic leukemia in blastic phase. 4
Totale 11.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.673
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.673
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.372 0 0 0 0 0 0 263 378 249 242 68 172
2020/20211.704 93 212 56 176 93 212 62 267 203 92 139 99
2021/20221.080 68 150 49 82 43 38 48 40 60 136 109 257
2022/20231.521 113 127 240 209 149 313 25 105 141 19 57 23
2023/20241.038 44 17 84 66 22 297 394 4 5 12 5 88
2024/2025950 59 117 203 109 338 123 1 0 0 0 0 0
Totale 11.519